We would love to hear your thoughts about our site and services, please take our survey here.
I think a lot of people owe you an apology, esp Calderkate. But they won't, ego, pride and arrogance will get in the way. Instead they'll resort back to insults if it rises by 0.5% tomorrow.
Might as well get the placing over and done with, better to do it now and hopefully get 20p a share rather than wait 12 months and raise 2p a share when cash balance will be dangerously low.
Board aren't buying either because it could be seen as insider info if suddenly next month they release an RNS saying dhsc have paid up in full with 9% interest, or they're aware that the dispute is likely to go against them.
Hoping its the former, even if dispute does find against nova, I can't see the SP dropping much below £2 so from here I think we're about as low as we can go, unless covid suddenly disappears. Then again this share is bonkers so I've given up trying to predict what might happen.
Kate - no need to be sarcastic.
Glad I didn't bother voting.
No direction, no communication, no promised acquisitions, no LFT, no sign of resolution. What an absolute shambles of a year after so much promise and progress in 2020. At least Colin King and wallbrook over at omega had the decency to warn investors not to pop down to the tesla dealership.
Not expecting to see another red dot in RNS tab until Feb. I just hope this silence is because they're waiting for resolution in next few months, not that they don't have a clue how to adapt to a world no longer scared of covid
@Jimi - Omega has branched in to the "Self Storage" business and got one over our main competitor Big Yellow by winning a Govt contract to store some machinery for 12 months, could be worth several grand a month with the Sq footage taken.
The type of Lateral Flow Antigen Test we provide is recognised as Hughes Health Care Sars-CoV-2 SARS-CoV-2 Antigen Test. It is registered through PHE.
Our Lateral Flow Antigen Tests accuracy, sensitivity and specificity can be found below:
Sensitivity: 96.8%
Specificity: 97.1%
Accuracy: 98.8%
The manufacturer of our Lateral Flow Antigen Tests is titled ACON Biotech (Hangzhou) Co. Ltd. Our Lateral Flow Antigen Tests are recognised under Annex 1
CK woke up this morning, chuckled to himself at the novacyt and avacta RNS, and then he thought "Wait, what's this deadline they're speaking of?"
Great read, good balanced arguments. I think the BBI partnership has been canned since they were bought out due to them not being able to meet costs (shows Al is aware that cost will be a primary factor) , but AS seems pretty keen to promote manufacturing capacity outside of UK which can be quickly scaled up.
Look at the logistics of getting tests to market with HGV driver shortages, manufacturing will need to take place close to demand, if we can have manufacturing bases in UK, spain, Asia etc if puts us at an advantage, a manufacturer only residing in far east or US will struggle to meet orders, govt ain't gonna charter planes forever, and alls gone quiet on that innova Welsh factory
If they wanted shareholders to vote in droves, they would have released Q3 this week if they were inline with or exceeding expectations, and can then turn around and say "support us, look how well things are going", GM could have left on a high, shareholders welcome new CEO with optimism.
Novacyt a pure covid play, built up on 1980's PCR technology. I think thats why institutions aren't interested, even at these prices. The fact is nova still haven't put their cash to good use and diversified or added complimentary acquisitions is concerning - perhaps they're waiting for GM to go and let the new guy drive the vision, or potential suitors aren't keen on how the company is being run. If a new 2nd gen vaccine appears, or some sort of cheap at home treatment is released it may mean less emphasis on testing.
The bod have killed any excitement I had for this share, though hoping for one last hurrah at £5-£6
Im as positive for avacta as anyone on here, but being on the frame work that allows purchasing for professional use by clinical organisations does not mean HUA is guaranteed nor imminent. It's still beyond avactas control, they might meet the criteria to submit for HUA but the decision makers aren't duty bound to accept, and if they're the same ones who approved innova, acon and orient gene, and barely allowing surescreen to scrape through, Im not putting too much hope on it.
Europe home approval and orders, perhaps via Spain, airlines, maybe US is what I'm looking for. If something comes from UK orders, whether thats through govt or finding them in the middle aisles of aldi for self testing then great, but I'm not fussed if we don't hear a word, and with the way the govt has ****ed over novacyt, mologic and Abingdon, as well as stringing omega along, large part of me thinks fook em, they can stick with the Chinese cack. Avacta tests are currently selling, might not be anywhere near the 5m units a month we're hoping for, but there's still a long way to go in this covid game, we're not even at half time yet with only 9% of third world with 1 jab. If score still 0-0, well we have our super sub - Ava early read out due end of the year and phase 1 results by q2.
"The company has the capacity to manufacture approximately 7 million tests per week, with plans to increase this to 14 million per week by the end of December."
I guess this is where omega steps in
GM has said in past that "shareholders are not his priority", in fact he probably sees us as a huge inconvenience (unless they need funding), as he's leaving I'm quite sure the new guy will be well aware of where GM was lacking and I'm willing to give them the benefit. Look at how the EUA bod in a recent rns pointed out "notes that the share price remains below the 26.5p price at which the $20m private placement", and promptly rose, even something small along those lines that shows the board cares about investors would help and make it more risky for those betting against the company
The ex-ceo of Omega seemed to think back in June there won't be a sovereign test (nicked from twatcher on ODX chat) , but instead the market opened up to multiple companies (I presume with HUA)
Bojo said they're working with UK industry, and most of the 112 or so listed are UK based (strange no odx or mologic listed though) so perhaps that is what he meant. Nova have had orders via the framework despite dispute with DHSC,
Guess it's this one
https://bidstats.uk/tenders/2021/W15/748945953